Moleculin completes Part A enrollment in MIRACLE AML trial, full data slated for Q1 2027
Moleculin Biotech announced that enrollment for Part A of its Phase 2/3 MIRACLE trial of Annamycin plus high‑dose cytarabine in relapsed or refractory AML is now complete. The company reported encouraging interim efficacy results and said the full 90‑patient Part A data readout is expected in the first quarter of 2027. Moleculin also indicated that it will need significant additional financing, for which it has no current commitments, to continue the trial and move into Part B.
Why it matters
The upcoming data readout could materially affect Moleculin’s valuation and future financing prospects, while the need for additional capital may pressure the company’s cash runway.
Key facts
- 1Enrollment in Part A of the MIRACLE trial is complete. stocktitan.net
- 2Interim efficacy results from Part A were reported as encouraging. tradingview.com
- 3Full 90‑patient Part A data readout is expected in the first quarter of 2027. investing.com
- 4Moleculin will require significant additional financing to conduct its clinical trials and has no current financing commitments. stocktitan.net
- 5The company plans to proceed with a Part B expansion after the Part A data readout. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.